Mirtazapina Flas Ratiopharm (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Flas Ratiopharm, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapina Flas Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts within the central nervous system to alleviate depressive symptoms in the major depressive disorder therapeutic area.

Major depressive disorder: reduces depressive mood, improves sleep and appetite, and increases overall functioning in adults.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness or light‑headedness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypotension or syncope - Hepatic dysfunction - Suicidal thoughts or behavior - Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should consider several safety aspects. - Hepatic function: assess liver enzymes in patients with hepatic impairment. - Weight monitoring: track body weight regularly due to potential gain. - Suicidality: monitor for emerging suicidal thoughts, especially early in treatment. - Elderly patients: start at low dose and watch for excessive sedation. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may increase mirtazapine plasma levels. - CYP inducers (e.g., carbamazepine, rifampicin): may reduce efficacy. - Antihistamines: may enhance anticholinergic burden. - Warfarin: monitor INR as mirtazapine can affect coagulation parameters.